Lv1
30 积分 2023-09-13 加入
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer
15天前
已完结
An FDA oncology analysis of immune activating products and first-in-human dose selection
16天前
已完结
Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity
23天前
已完结
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model
23天前
已完结
Toll-like receptor control of the adaptive immune responses
27天前
已完结
CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy
28天前
已完结
GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma
1个月前
已完结
GDF15 is still a mystery hormone
1个月前
已完结
Development of a 10 g/L process for a difficult-to-express multispecific antibody format using a holistic process development approach
2个月前
已完结
Hepatitis B surface antigen level identifies patients with inactive chronic hepatitis B from Asia with HCC risk below surveillance threshold
3个月前
已完结
皖公网安备34019202002308
